The prevalence of duplicate participants in clinical trials poses significant risks, compromising the integrity of data and the safety of the patients involved. To delve into this matter, we spoke with Kerri Weingard, a seasoned veteran in the field and the co-founder of Verified Clinical Trials (VCT), who brings a wealth of knowledge and experience. In this …
January 30, 2025 07:07 ET | Source: Velocity Clinical Research, Inc.Follow DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ …
In the dynamic world of clinical research, ensuring data integrity and participant safety is paramount. One of the most significant challenges faced by clinical trials today is the issue of duplicate subjects in clinical trials—participants who enroll in multiple studies simultaneously or consecutively without proper washout periods. This practice can jeopardize study outcomes, compromise data …
We’re excited to announce that Verified Clinical Trials (VCT) will be exhibiting and hosting a special panel discussion focused on the growing challenges of duplicate and professional subjects in vaccine clinical trials. Vaccine clinical trials present a unique set of challenges, particularly when it comes to subject verification. Unlike many other clinical studies, vaccine trials …
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple …
Clinical trials around the world face challenges from professional research subjects or dual enrollment in clinical trials. One group of subjects that have high rates of participation in clinical research are subjects who enroll in multiple trials for the purpose of generating income through study payments or using clinical trials as medical care. These subjects …
WHAT IF 10% of your research subjects for your clinical trial were duplicate subjects or professional research subjects, participating in other clinical trials simultaneously, not taking the study IP, providing false answers to the coordinator just to try and stay in the study, and currently in a phase 1 healthy volunteer study at the same …
Without a “tool” such as the Verified Clinical Trials (VCT) global research subjects database registry, detecting duplicate subjects and protocol violations based upon prior study history or prior study drug (IP) exposure is impossible. VCT proactively detects these issues at the time of screening before costly screening procedures occur. The protections continue the entire duration …
From phase 1 through phase 4 drug development, the issue of duplicate subjects in clinical trials exists. Verified Clinical Trials (VCT). www.verifiedclinicaltrials.com is here to prevent these issues and promote safety and data quality. Duplicate subjects in CNS clinical trials is especially needed, but VCT protects most therapeutic areas. Characteristics of duplicate subjects are not …
Duplicate subjects in clinical trials is unfortunately a common issue that affects all trials from most every indication and across all phases of clinical trials research. These professional research subjects can be prevented by using Verified Clinical Trials (VCT) the global research subject registry. Nearly all of the phase 1 units across the United States …
